Posted: 08/08/2016

Combination Immunotherapies Fight Cancer

Cancer_research_concept

Recently, pharmaceutical companies Bristol-Meyer Squibb and AbbVie announced a collaborative effort to determine if a combination of specific immunotherapy drugs can effectively treat relapsed extensive-stage small cell lung cancer. The study is expected to begin enrolling patients sometime this year.

The drugs involved in the treatment are AbbVie’s Rova-T and Bristol-Meyer Squibb’s Opdivo and Opdivo-Yervoy treatment combination. Rova-T (rovalpituuzumab tesirine) is being studied as a biomarker-specific antibody drug conjugate that identifies cancer stem cells with DLL3 protein (Delta like protein 3) in order deliver a cytotoxic agent that destroys tumor-initiating and bulk-tumor cells. Opdivo, an immune-checkpoint 1 inhibitor, and Yervoy, an immune-checkpoint 4 inhibitor, currently target unresectable or metastatic melanoma.


Opdivo Immunotherapy Medication.


Immune-checkpoint inhibitors such as Opdivo and Yervoy essentially jumpstart the immune system by helping identify particular proteins associated with cancer cells so they can be attacked. In this study, DLL3 proteins are the target, as they are found in the tumors of more than 80% of those with small cell lung cancer, the proteins Rova-T is specifically manufactured to address.

Rova-T is currently being tested as a third-line treatment option for certain types of melanoma. New testing for its value as a first-line SCLC option begins in the near future. Because it targets DLL3, it is hoped it will be effective in treating several tumor types, as well as metastatic melanoma, glioblastoma multiforme and some prostate, pancreatic and colorectal cancers.

Opdivo (nivolumab) was the first immune-protein inhibitor and is currently used for treating:

• Both BRAF V600 wild-type and mutation-positive unresectable or metastatic melanoma,Metastatic non-small cell lung cancer that has progressed following platinum-based chemotherapy
• Advanced renal cell carcinoma in those having already received anti-angiogenic therapy
• Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin.

Yervoy (ipilimumbab) is a CTLA-4 immune checkpoint inhibitor recommended for patients with unresectable or metastatic melanoma. The combination of OPDIVO and YERVOY is used to treat of patients with unresectable or metastatic melanoma.

Both drugs work by binding to checkpoint receptors found on activated T-cells, blocking the binding of PD-L1 and PD-L2 and preventing interference with an anti-tumor immune response which, in this study, will be Rova-T.

It is hoped that the initial clinical program phases will demonstrate that a regimen of a cancer stem cell antibody drug conjugate along with immune checkpoint inhibitors will safely and effectively enhance the impact of immunotherapy beyond currents levels. And, if successful, it will lead to greater advances in cancer treatment options, especially for those cancers that have limited resources for treatment. 

By HelpRx Staff Writer

Get your Prescription Discount Card and automatically SAVE on over 50,000 drugs nationwide.

Helprx_branded_card_desktop Click-here-redbg

About the HelpRx.info Blog

HelpRx.info is staffed by experts in the prescription medication industry. Get the latest health, medical news and pharmaceutical news that can save you money and allow you to take charge of your healthcare. With frequent updates about the prescription drug industry as well as medicine news, you'll gain an insider look into the industry and learn more about how to get the best price on your prescriptions while not sacrificing quality. Subscribe to the HelpRx.info pharmacy blog through our RSS feed or get updates by liking HelpRx.info on Facebook and following HelpRx.info on Twitter.

About HelpRx

Our discounts provide you access to negotiated prices on your prescription drugs at your local pharmacy. We can provide these because we're partnered with OptumRx, a BIG pharmacy benefit provider that provides prescription coverage for MILLIONS of people like you.

About ScriptRelief

Script Relief, the creator of the NPSN card and HelpRx discounts, helps consumers save an average of 50%, and up to 75%, off their prescriptions.

Popular Post

 

Get your Prescription Discount Card and automatically SAVE on over 50,000 drugs nationwide.

Helprx_branded_card_desktop Click-here-redbg

Popular Post

 

About the HelpRx.info Blog

HelpRx.info is staffed by experts in the prescription medication industry. Get the latest health, medical news and pharmaceutical news that can save you money and allow you to take charge of your healthcare. With frequent updates about the prescription drug industry as well as medicine news, you'll gain an insider look into the industry and learn more about how to get the best price on your prescriptions while not sacrificing quality. Subscribe to the HelpRx.info pharmacy blog through our RSS feed or get updates by liking HelpRx.info on Facebook and following HelpRx.info on Twitter.

About HelpRx

Our discounts provide you access to negotiated prices on your prescription drugs at your local pharmacy. We can provide these because we're partnered with OptumRx, a BIG pharmacy benefit provider that provides prescription coverage for MILLIONS of people like you.

About ScriptRelief

Script Relief, the creator of the NPSN card and HelpRx discounts, helps consumers save an average of 50%, and up to 75%, off their prescriptions.

Helprx_savings_logo

About Our Savings:

HelpRx.info is a discount pharmacy service, partnered with a leading pharmacy benefit manager. We negotiate lower prices on prescription medications, that we pass on to our members for free. There is no cost to use our cards and coupon, and anyone can take advantage of our discounts, regardless of healthcare coverage.

Our savings assurance of “up to 75% off” comes from historical data from actual claims. This data includes savings for both brand name and generic medications.